There certainly are a few reasons to be pessimistic about Insys Therapeutics (NASDAQ: INSY).
Its cannabidiol drug, Syndros, still hasn’t been scheduled by the U.S. Drug Enforcement Agency (DEA). The company recently announced a delay in the release of its fourth-quarter and full 2016 results. And Insys Therapeutics stock has dropped more than 30% over the last few weeks.
Despite all of that, could Insys actually be the best marijuana stock to buy right now? I think so. Here’s why.